|Lpath Rises 30%|
|By Staff and Wire Reports|
|Wednesday, 23 November 2011 19:54|
Shares of Lpath (OTCBB:LPTN) rose 30.43% to $1.20+0.28. Last Thursday, November 17th, we told our readers about the firm, which appears to be a potential acquisition target for Big Pharma. The firm's therapeutics platform is showing strong data which suggests that their drug-discovery engine has a unique ability to bind to and inhibit bioactive lipids that contribute to various diseases. Pfizer Morgan Joseph, a firm with research analysts who distinguish themselves by zeroing in on quality companies with growth prospects and which often present special situations, recently rated the firm a "Buy" with a price target of $8.
The Company's iSONEP drug candidate after published data shows that the drug appears to mitigate the scar tissues and inflammation associated with age-related macular degeneration. In fact, Phase 1 results suggest iSONEP might actually “melt away” less mature lesions and those with occult-type disease represent ~70-80% of the market, but close to 90% of the newly diagnosed patients. Pfizer (NYSE: PFE ) has recently established a partnership (possible $500+M) with the firm for their ocular drug candidate.
Shares are now only 22.58% from their 52-Wk high ($ 1.55 ), with very minor resistance to overcome at the $1.25 level.
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, completed a pre-IND (Investigational New Drug) meeting with the FDA on November 22, 2011 to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) announce today the signing of an exclusive commercialization and licensing agreement for the registration and marketing of perifosine, Aeterna Zentaris' lead anti-cancer compound, for the MENA (Middle East and North Africa) region.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the 23rd Annual Piper Jaffray Health Care Conference in New York City at 11:30 a.m. Eastern on Wednesday, November 30, 2011.
Cannabis Science, Inc. (OTCBB; CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce the successful release of the second Cannabis Science brand formulation.
Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Piper Jaffray 23rd Annual Health Care Conference in New York on November 30, 2011.
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Piper Jaffray 23rd Annual Healthcare Conference at 2:30 p.m. EST on November 30, 2011, in New York City.
Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference to be held on Tuesday, December 6, 2011 at the St. Regis Hotel in San Francisco.
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible catheter robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced that President and CEO Bruce Barclay is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference.
Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging announced today that it has sold the first system of five ordered to be installed in Mexico.
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, at 3:00 p.m. ET.
Marijuana Inc (PINKSHEETS: HEMP) is proud to applaud Presidential candidates, including Republican Hermain Cain, for his stance on the regulation of medical marijuana dispensaries, stating that those decisions are best left to the states, as reported in the November 16 issue of the Huffington Post (See article).
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2011 Piper Jaffray Health Care conference, to be held November 29 - 30, 2011 in New York City. Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer will present a 30 minute corporate overview on November 29th at 10 AM ET.
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announcedthat it has appointed several executives to its global team of late phase and observational research experts in PAREXEL's PACE™ (Peri-Approval Clinical Excellence) group.
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that management is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference that will be held on November 29th and 30th at The New York Palace in New York City, and to participate in HK/China Mini Conference 2011 (Healthcare) on December 1, 2011 at Island Shangri-La Hotel, Hong Kong.
SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announces the acquisition of business and brands of privately owned Novatrend Medicament Pvt. Ltd.
Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that James Levine, Executive Vice President and Chief Financial Officer, will present at the upcoming Baird 2011 Clean Technology Conference.